BC Innovations | Mar 1, 2018
Translation in Brief

A path less traveled

A team from PSL Research University has shown how a nitric oxide (NO)-donating compound steers TNFα signaling away from a pro-survival pathway towards one that promotes death in cancer cells. The findings suggest NO-donors could...
BC Week In Review | Oct 10, 2016
Clinical News

Glyceryl trinitrate: Phase II data

Top-line data from a double-blind, crossover, U.K. pivotal Phase II trial in 232 patients with ED showed that 0.2% topical MED2002 applied immediately before sexual intercourse met the primary endpoint of improving the EF domain...
BC Week In Review | May 16, 2016
Clinical News

Glyceryl trinitrate: Completed Phase II enrollment

Futura completed enrollment of 192 patients in a double-blind, placebo-controlled, crossover, European pivotal Phase II trial evaluating >=4 topical applications of 300 mg MED2002 prior to intercourse over 4 weeks. Futura Medical plc (LSE:FUM), Guildford,...
BioCentury | Apr 4, 2016
Finance

2Q milestones

2Q milestones Company Product Indication Event Milestone Ablynx N.V. (Euronext:ABLX) ALX-0171 Respiratory syncytial virus (RSV) infection Ph I/IIa data 2Q16 Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) Nuplazid pimavanserin Parkinson's disease psychosis (PDP) PDUFA date 5/1/16 Acucela Inc....
BioCentury | Jan 11, 2016
Finance

Sowing season

Stephen Hansen, Associate Editor   BUYSIDE VIEW XXIV While the biotech sector's three-year rocket ride isn't likely to continue in 2016, fund managers are still anticipating a slew of high-profile milestones in the New Year....
BC Week In Review | Jul 13, 2015
Clinical News

Eroxon: Phase III started

Futura began a double-blind, placebo-controlled, crossover, European Phase III trial to evaluate 4 doses of 300 mg topical MED2002 over 4 weeks in 192 patients. Futura Medical plc (LSE:FUM), Guildford, U.K.   Product: Eroxon ( MED2002...
BC Innovations | Jul 14, 2011
Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Poisoning Intrinsic smooth muscle pump Mouse and human studies suggest nitric oxide (NO)-releasing agents could help treat poisoning from snake bite. In humans with a...
BC Week In Review | May 2, 2005
Clinical News

Avanafil: Phase II data

In a double-blind, placebo-controlled, crossover Phase II study in 101 healthy males who received sublingual 0.4 mg glyceryl trinitrate (GTN), pretreatment with avanafil had less effect on HR and systolic BP compared to Viagra sildenafil....
Items per page:
1 - 8 of 8